ClinicalTrials.gg
RecruitingNCT04516057NAB-ITUpdated Nov 6, 2026

Nabilone for Agitation Blinded Intervention Trial

A Phase 3 interventional study of Nabilone and Placebo in Alzheimer Disease and Agitation, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 8 sites in Canada. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Sunnybrook Health Sciences Centre · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.
Updated Nov 6, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre — 8 open to participants now, 8 under way, 1 of them phase 3. Alzheimer Disease · Sunnybrook Health Sciences Centre.

Planned enrollment
2nd of 13
112 · median 40
Started
2021
the only one that year
Phase 3
2 of 16
1 open now
Registered
10th of 16
by date

Among the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 3, and was the 10th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by Sunnybrook Health Sciences Centre, or all of them as a file.
02

Study summary

This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increased caregiver burden, poorer quality of life, and increased risk of death. In addition, current pharmacological options show only modest efficacy and elevated risks of adverse events. Therefore, identifying safer and more effective treatments for agitation in AD is a clinical and research priority.

Nabilone is a synthetic cannabinoid that is Health Canada-approved to treat chemotherapy-induced nausea and vomiting.

The PI's research group completed a 6-week double-blind placebo-controlled randomized cross-over pilot trial in 38 patients with moderate-to-severe AD, providing the first preliminary evidence regarding the safety and efficacy of nabilone in this population. They found that nabilone significantly improved agitation, overall neuropsychiatric symptoms, and caregiver distress. That study was limited by its sample size and questions remain regarding the efficacy of nabilone for nutrition and pain and predictors of response. However, the promising preliminary findings encourage a pivotal, practice-changing phase III trial to inform clinical practice.

Participants in this study will be randomized to receive either nabilone or a placebo for 8 weeks. In addition to looking at the effectiveness of nabilone in treating agitation, the researchers will also look at whether it is beneficial for other relevant outcomes for patients with AD including overall neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, and pain. Participants will also be followed for 8 weeks following completion of the study treatment.

03

Conditions studied

  • Alzheimer Disease
  • Agitation

Keywords

  • Cannabis
  • Cannabinoid
  • THC
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females ≥55 years of age; females must be
  2. -5 (DSM 5) criteria for Major Neurocognitive Disorder due to AD. Patients with Major Neurocognitive Disorder due to multiple etiologies (AD and vascular) will be included
  3. sMMSE ≤24
  4. Presence of agitation based on the IPA definition
  5. If treated with cognitive-enhancing medications (cholinesterase inhibitors and/or memantine), dosage must be stable for at least 3 months prior to study randomization
  6. Availability of a primary caregiver to accompany the participant to study visits and to participate in the study. The primary caregiver must be sufficiently proficient in English to complete the required study assessments, as per investigator judgement.

Exclusion criteria

Exclusion Criteria:

  1. Change in psychotropic medications less than 1 week prior to study randomization (e.g., concomitant antidepressants)
  2. to cannabinoids, e.g. allergies to cannabis and cannabis products, potential drug-drug interactions
  3. Current uncontrolled cardiovascular disease (e.g. uncontrolled hypertension, ischemic heart disease, arrhythmia and severe heart failure), as per investigator assessment
  4. Current significant liver disease, as per investigator assessment
  5. Presence or history of other psychiatric disorders or neurological conditions (e.g. psychotic disorders, schizophrenia, stroke, epilepsy)
  6. Participants currently meeting DSM 5 criteria for Major Depressive Episode (MDE)
  7. Previous or current abuse of/dependence on marijuana
  8. Clinically significant delusions and/or hallucinations (NPI-NH delusion/hallucinations subscore ≥4)
  9. Reported recreational use of marijuana or other cannabis products within 3 months prior to study randomization
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Nabilone Arm

    Participants randomized to the nabilone arm will be titrated up to a maximum dose of 2 mg/day.

    Drug: Nabilone

  • Placebo comparator
    Placebo Arm

    Participants randomized to the placebo arm will receive placebo capsules.

    Other: Placebo

Interventions

  • After the screening period, participants randomized to the nabilone arm will receive nabilone for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.

    Also known as: Cesamet

  • OtherPlacebo

    After the screening period, participants randomized to the placebo arm will receive placebo capsules for 8 weeks. Participants will then be followed for 8 weeks following completion of the study treatment.

06

What researchers measure

Primary outcomes

  1. Agitation - Cohen-Mansfield Agitation Inventory (CMAI)

    A 29-point scale that measures agitation in two dimensions, verbal and physical, each of which having two poles, aggressive and non-aggressive. Scores range from 29-203 points, with a higher score indicating a worse outcome. This includes the CMAI IPA Agitation Score \& CMAI IPA Delphi Modification, which are derived from the CMAI.

    Time frame: Baseline (0 Weeks) to 8 Weeks

Secondary outcomes

  1. Behaviour - Neuropsychiatric Inventory - Nursing Home (NPI-NH)

    A widely used assessment of behaviour disturbances in dementia, including: apathy, agitation, delusions, hallucinations, depression, euphoria, aberrant motor behaviour, irritability, disinhibition, anxiety, sleeping, and eating. The frequency and severity of these symptoms are judged on a 4-point and 3-point scale, respectively. Scores range from 0-144 points, with a higher score indicating a worse outcome.

    Time frame: Baseline (0 Weeks) to 8 Weeks

  2. Cognition - Standardized Mini-Mental State Examination (sMMSE)

    Measures global cognition, and assesses orientation to time and place, immediate recall, short-term verbal memory, calculation, language, and construct ability. Scores range from 0-30 points, with a lower score indicating a worse outcome.

    Time frame: Baseline (0 Weeks) to 8 Weeks

  3. Weight

    Weight (kg) is collected at each visit

    Time frame: Baseline (0 Weeks) to 8 Weeks

  4. Nutritional Status - Mini Nutritional Assessment - Short Form (MNA-SF)

    A structured interview consisting of 6 items that categorizes patients as malnourished, at risk of malnutrition, or of normal nutritional status. Scores range from 0-14 points, with a lower score indicating a worse outcome.

    Time frame: Baseline (0 Weeks) to 8 Weeks

  5. Pain - Pain Assessment Checklist for Seniors with Limited Ability to Communicate-II (PACSLAC-II)

    A 31-item observer-rated scale assessing facial expressions, activity/body movements, social/personality/mood indicators and mental status changes. Scores range from 0-31 points, with a higher score indicating a worse outcome.

    Time frame: Baseline (0 Weeks) to 8 Weeks

  6. Global Change - Alzheimer's Disease Cooperative Study - Clinical Global Impression of Severity/Change (ADCS-CGIS/C)

    A commonly-used clinician-rated scale that quantifies disease severity and clinical change (worsening, no change, or improvement), based on information regarding the patient's medical history, cognition, behaviour, and function. Numerical scores are not assigned.

    Time frame: Baseline (0 Weeks) to 8 Weeks

Other outcomes

  1. Sedation - Udvalg for Kliniske Undersøgelser (UKU) Side-Effect Rating Scale

    Sedation will be measured using the Sleepiness/Sedation subscale of the UKU-Side Effect Rating Scale. The UKU is a clinician-rated scale that assesses the side effects of psychopharmacological medications. Scores range from 0-3, with a higher score indicating more sleepiness/sedation.

    Time frame: Baseline (0 Weeks) to 8 Weeks

07

Study locations

5 of 8 sites recruiting
08

References and documents

Publications

  • Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, Lanctot KL. Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. Am J Geriatr Psychiatry. 2019 Nov;27(11):1161-1173. doi: 10.1016/j.jagp.2019.05.002. Epub 2019 May 8. PubMed 31182351 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in the article after deidentification (text, tables, figures and appendices)

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. They will be able to access individual participant data that underlie the results reported in the publication after deidentification. Proposals may be submitted to the coordinating centre/central contact person up to 36 months following publication.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2027, 82 months after the start.

Of 101 phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 73. This study's planned 82 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Apr 2027 → Dec 2027 and completion Apr 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 17, 2020
StartActual
Feb 1, 2021
Primary completionEst.
Dec 2027was Apr 2027
CompletionEst.
Dec 2027was Apr 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. St. Michael's Hospital is now Terminated
Show 2 added (2 Canada)
  • Geras Centre for Aging Research, Hamilton Health Sciences · Hamilton, Canada
  • The University of Ottawa Institute of Mental Health Research at The Royal · Ottawa, Canada
Nov 6, 2026
Primary completion
Apr 2027→Dec 2027
Nov 6, 2026
Study completion
Apr 2027→Dec 2027
Nov 6, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionWeight: how it is measured was reworded
Nov 6, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Centre for Addiction and Mental Health · Toronto, CanadaContact N•••@camh.ca→N•••@camh.ca
  • St. Michael's Hospital · Toronto, CanadaContact removed A•••@unityhealth.to
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    2 sites added. St. Michael's Hospital is now Terminated
    Show 2 added (2 Canada)
    • Geras Centre for Aging Research, Hamilton Health Sciences · Hamilton, Canada
    • The University of Ottawa Institute of Mental Health Research at The Royal · Ottawa, Canada
    Primary completion Apr 2027→Dec 2027
    Study completion Apr 2027→Dec 2027
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionWeight: how it is measured was reworded
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Centre for Addiction and Mental Health · Toronto, CanadaContact N•••@camh.ca→N•••@camh.ca
    • St. Michael's Hospital · Toronto, CanadaContact removed A•••@unityhealth.to
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04516057
Collaborators
Alzheimer's Drug Discovery Foundation
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Feb 1, 2021
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

NAB-IT Coordinating Centre
Contact
NAB-IT@sunnybrook.ca
416-480-6100 ext. 5630
Krista L. Lanctot, PhD
principal investigator · Sunnybrook Research Institute
Giovanni Marotta, MD
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nabilone

Start the discussion